Eisai (company)

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Eisai Co., Ltd.
Native name エーザイ株式会社
Type Public KK (TYO: 4523)
Industry Pharmaceuticals
Founded 1936
Headquarters Tokyo, Japan
Key people Haruo Naito, President & CEO
Revenue Increase ¥ 781.7 billion JPY (FY 2008)
Net income Increase ¥ 47.7 billion JPY (FY 2008)
Employees 10,962 (2008)
Website www.eisai.com

Eisai Co., Ltd. (エーザイ株式会社 Ēzai Kabushiki-gaisha?) is a Japanese pharmaceutical company, ranking among the top 25 in the world by revenue and achieving $8 billion USD in sales for the fiscal 2008 year[ambiguous]. Headquartered in Tokyo, Japan, it has some 10,000 employees, among them about 1,500 in research. Eisai is a member of the Topix 100 and Nikkei 225 indices.


Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995.[citation needed]

In 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for $3.9 billion USD. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel.


Eisai head office, Tokyo

Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary Eisai Inc. is headquartered in Woodcliff Lake, New Jersey.

Eisai maintains medical research headquarters in Woodcliff Lake, New Jersey as well as locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute is based.

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.


Some of the key products that Eisai produces or markets with partners include:

  • Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease
  • Actonel (risedronic acid) - Osteoporosis (Japan)
  • Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting
  • Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients
  • Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut Syndrome
  • Belviq (lorcaserin) - Obesity
  • Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism
  • Fycompa (perampanel) - Partial-onset seizures
  • Halaven (eribulin) - Metastatic breast cancer
  • Iomeron - Non-ionic contrast medium
  • Methylcobal - Peripheral neuropathy
  • Myonal - Muscle relaxant
  • Selbex - Gastric ulcers and gastritis
  • Zonegran (zonisamide) - Partial-onset seizures
  • Gliadel Wafer (carmustine)- Treatment for Brain Tumors

Along with these select prescription drugs, which account for 90% of the company's sales, Eisai markets Chocola BB, Travelmin, Nabolin, Juvelex, Saclon, and Selbelle tablets consumer products.


Aricept accounted for 40% of Eisai's revenue as of March 2010.[1] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[1] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[1]

Pipeline candidates[edit]

Some of Eisai's pipeline candidates include:

  • AS-3201 - Diabetic neuropathy
  • E2007 - Epilepsy & migrane prevention
  • E5564 - Severe sepsis


  1. ^ a b c Kanoko Matsuyama (25 April 2011). "Eisai Aricept Patch for Alzheimer’s Isn’t Ready for Approval". Bloomberg. Retrieved 25 April 2011. 

External links[edit]